DARZALEX® (daratumumab)
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-release Tablets CII
DARZALEX® (daratumumab)
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVEGA TRINZA® (paliperidone palmitate) extended-release injectable suspension 273 mg, 410 mg, 546 mg, or 819 mg
INVEGA TRINZA®
INVOKAMET® (canagliflozin/metformin HCl) tablets
INVOKAMET® XR (canagliflozin/metformin HCl extended-release) tablets
INVOKAMET® XR
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
OLYSIO® (simeprevir)
OneTouch® Meters and Test Strips
ORTHO TRI-CYCLEN® Lo (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® Lo
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PREZCOBIX® (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) tablets
PROCRIT® (epoetin alfa)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab)
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT® (siltuximab)
TOPAMAX® (topiramate) Tablets
XARELTO® (rivaroxaban)
YONDELIS® (trabectedin)
ZYTIGA® (abiraterone acetate)

Need help paying for your DARZALEX® (daratumumab) prescription?

We want to guide you to programs that may help. Here you'll find the financial assistance programs available for DARZALEX®. We have also listed most of the eligibility requirements for each, so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their websites to learn more.

Janssen CarePath

877-CarePath

(877-227-3728)

Monday-Friday, 8 AM to 8 PM ET

To view programs that are best suited for you, select your insurance status for DARZALEX® or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for DARZALEX® or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are affiliated with Janssen.

They are updated on a regular basis. Be sure to visit the program site for additional information.

Janssen CarePath Savings Program for DARZALEX®

The Janssen CarePath Savings Program for DARZALEX® may provide a rebate for your out-of-pocket DARZALEX® costs. If eligible, you will pay no more than $10 per infusion. For infusions 1-8, you pay $5 per infusion. For infusions 9+, you pay $10 per infusion. Maximum benefit per calendar year is $15,000. Not valid for patients enrolled in Medicare or Medicaid.

View eligibility requirements

Eligibility Requirements for Janssen CarePath Savings Program for DARZALEX®

You may be eligible if:

  • You have been prescribed DARZALEX®
  • You currently have commercial or private health insurance that covers a portion of medication costs for DARZALEX®
  • Additional restrictions apply

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) provides free prescription medications to eligible individuals who do not have insurance coverage for their medicines and do not have adequate financial resources to pay for them. Please contact a JJPAF program specialist at 800-652-6227 (9 AM to 6 PM ET) or visit the foundation website at JJPAF.org to see if you might qualify for assistance.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and coinsurance. Find out if your state has a program that can help you.

CancerCare

CancerCare® is the leading national organization dedicated to providing free support services, including counseling, support groups, educational workshops, publications and financial assistance, to anyone affected by cancer.

Good Days from CDF®

This foundation provides financial assistance to those eligible for co-pays and travel costs associated with treatment.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for DARZALEX®
    AND
  • You are taking DARZALEX® to treat multiple myeloma

Patient Access Network Foundation

The Patient Network Foundation offers help and hope to people with chronic or life-threatening illness for whom cost limits access to breakthrough medical treatments.

Patient Advocate Foundation

Provides effective medication and arbitration services to patients to remove obstacles to health care, including medical debt crisis, insurance access issues and employment issues, for patients with chronic, debilitating, and life-threatening illnesses.

Leukemia & Lymphoma Society (LLS)

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

December 21, 2016
Expand
Expand

What is DARZALEX® (daratumumab)?

DARZALEX® is a prescription medicine used to treat multiple myeloma:

  • In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma.
  • Alone in people who have received at least 3 prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent.

It is not known if DARZALEX® is safe and effective in children.

Important Safety Information for DARZALEX® (daratumumab)

What should I tell my healthcare provider before taking DARZALEX® (daratumumab)?

Before you receive DARZALEX®, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX®?

What are the possible side effects of DARZALEX®?

DARZALEX® may cause serious reactions, including:

The most common side effects of DARZALEX® include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of DARZALEX®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX® that is written for health professionals.

Please see Important Product Information.

063321-161115

What is DARZALEX® (daratumumab)?

DARZALEX® is a prescription medicine used to treat multiple myeloma:

  • In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma.
  • Alone in people who have received at least 3 prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent.

It is not known if DARZALEX® is safe and effective in children.

Important Safety Information for DARZALEX® (daratumumab)

What should I tell my healthcare provider before taking DARZALEX® (daratumumab)?

Before you receive DARZALEX®, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX®?

What are the possible side effects of DARZALEX®?

DARZALEX® may cause serious reactions, including:

The most common side effects of DARZALEX® include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of DARZALEX®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX® that is written for health professionals.

Please see Important Product Information.

063321-161115